Fulgent Genetics, Inc. (FLGT) News & Corporate Actions | Announcements, Board Meetings, Splits, Bonuses, Rights Issues

{
"main_header": {
"sid": 1243530,
"name": "Fulgent Genetics, Inc.",
"stock_name": "Fulgent Genetics, Inc.",
"full_name": "Fulgent Genetics, Inc.",
"name_url": "stocks-analysis/fulgent-genetics-inc",
"exchange": 210,
"exchangecode": "NAS",
"country_id": 2,
"currency": "USD",
"cmp": "28.30",
"chg": -0.1,
"chgp": "-0.35%",
"dir": -1,
"prev_price": "28.40",
"mcapval": "681.66",
"mcap": "Micro Cap",
"scripcode": "",
"symbol": "",
"ind_name": "Pharmaceuticals & Biotechnology",
"ind_code": 3365,
"indexname": "S&P 500",
"isin": "US3596641098",
"curr_date": "Dec 04",
"curr_time": "",
"bse_nse_vol": "320.76 k",
"exc_status": "Active",
"traded_date": "Dec 04, 2025",
"traded_date_str": "2025 12 04",
"score": "",
"scoreText": "",
"Live": 0,
"market_time": 0,
"is_blur": 1,
"is_blur_class": "blur-registerF-score-header",
"is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/fulgent-genetics-inc-1243530-210&utm_source=Spage_Header_Score",
"mojoone": {
"ismore": 0
}
},
"news": {
"results": [
{
"title": "Fulgent Genetics Hits New 52-Week High of $27.36, Reflecting Strong Growth",
"link": "https://www.marketsmojo.com/news/stocks-in-action/fulgent-genetics-hits-new-52-week-high-of-2736-reflecting-strong-growth-3686484",
"imagepath": "https://i.marketsmojo.com/newsimg/2025/11/FulgentGenetics_priceRelatedfactors_3686484.png",
"date": "2025-11-10 17:21:52",
"description": "Fulgent Genetics, Inc. has achieved a new 52-week high, reflecting a strong performance over the past year. With a market capitalization of USD 682 million, the company, despite being loss-making, demonstrates resilience in the competitive biotechnology sector, highlighted by its financial metrics and recent stock performance."
},
{
"title": "Is Fulgent Genetics, Inc. technically bullish or bearish?",
"link": "https://www.marketsmojo.com/news/stocks-in-action/is-fulgent-genetics-inc-technically-bullish-or-bearish-3673692",
"imagepath": "",
"date": "2025-11-05 11:22:52",
"description": "As of 31 October 2025, the technical trend for Fulgent Genetics, Inc. has changed from bullish to mildly bullish. The weekly MACD is bullish, while the monthly MACD is mildly bullish, indicating a positive momentum but with some weakening. The Bollinger Bands are bullish on both weekly and monthly time frames, supporting the upward price movement. Daily moving averages are also bullish. However, the RSI shows no signal on both weekly and monthly charts, and Dow Theory indicates no trend in either time frame. \n\nIn terms of performance, Fulgent Genetics has underperformed the S&P 500 over the past year and three to five years, with returns of 5.88% and -39.61% respectively, compared to the S&P 500's 19.89% and 76.66%. Overall, the current stance is mildly bullish, but the strength is tempered by mixed signals and historical underperformance...."
},
{
"title": "Fulgent Genetics, Inc. Experiences Revision in Stock Evaluation Amid Market Dynamics",
"link": "https://www.marketsmojo.com/news/stocks-in-action/fulgent-genetics-technical-trend-shifts-from-bullish-to-mildly-bullish-amid-price-increase-3671409",
"imagepath": "https://i.marketsmojo.com/newsimg/2025/11/FulgentGenetics_technicaldot_3671409.png",
"date": "2025-11-04 16:08:37",
"description": "Fulgent Genetics, Inc. has recently revised its evaluation amid current market conditions. The stock price has seen a slight increase, with a year-to-date return surpassing the S&P 500. However, its longer-term performance remains below the broader market, reflecting ongoing challenges within the company and industry."
},
{
"title": "Is Fulgent Genetics, Inc. technically bullish or bearish?",
"link": "https://www.marketsmojo.com/news/stocks-in-action/is-fulgent-genetics-inc-technically-bullish-or-bearish-3670868",
"imagepath": "",
"date": "2025-11-04 11:34:23",
"description": "As of 31 October 2025, the technical trend for Fulgent Genetics, Inc. has changed from bullish to mildly bullish. The weekly MACD is bullish, while the monthly MACD is mildly bullish, indicating a positive momentum. The Bollinger Bands and KST also reflect a mildly bullish stance across both weekly and monthly time frames. Moving averages are mildly bullish on a daily basis. However, the RSI shows no signal for both weekly and monthly periods, suggesting a lack of strong momentum.\n\nIn terms of performance, Fulgent Genetics has underperformed the S&P 500 over the past year and three to five years, with returns of 6.94% and -39.01% respectively, compared to the S&P 500's 19.89% and 76.66%. However, it has outperformed the S&P 500 year-to-date with a return of 25.12% versus 16.30%. Overall, the current technical stance is mildly bullish, but the long-term performance raises caution...."
},
{
"title": "Is Fulgent Genetics, Inc. technically bullish or bearish?",
"link": "https://www.marketsmojo.com/news/stocks-in-action/is-fulgent-genetics-inc-technically-bullish-or-bearish-3666475",
"imagepath": "",
"date": "2025-11-03 11:34:12",
"description": "As of 31 October 2025, the technical trend for Fulgent Genetics, Inc. has changed from bullish to mildly bullish. The weekly MACD and KST indicators are bullish, while the monthly MACD and KST are mildly bullish. The Bollinger Bands and moving averages also reflect a mildly bullish stance across both weekly and monthly time frames. The Dow Theory supports a mildly bullish outlook as well. \n\nIn terms of performance, the stock has underperformed the S&P 500 over the past week and month, with returns of -5.43% and -4.47% respectively, while it has outperformed the S&P 500 year-to-date with a return of 21.55% compared to 16.30%. However, over longer periods, the stock has significantly underperformed the benchmark. Overall, the current technical stance is mildly bullish...."
},
{
"title": "Is Fulgent Genetics, Inc. technically bullish or bearish?",
"link": "https://www.marketsmojo.com/news/stocks-in-action/is-fulgent-genetics-inc-technically-bullish-or-bearish-3664597",
"imagepath": "",
"date": "2025-11-02 11:18:48",
"description": "As of 31 October 2025, the technical trend for Fulgent Genetics, Inc. has changed from bullish to mildly bullish. The weekly MACD is bullish, while the monthly MACD is mildly bullish. The Bollinger Bands and KST indicators are also showing mildly bullish signals across both weekly and monthly time frames. Moving averages on the daily chart indicate a mildly bullish stance. However, the RSI does not provide any signals for either time frame. \n\nIn terms of performance, Fulgent Genetics has underperformed the S&P 500 over the past week and month, with returns of -5.43% and -4.47% respectively, while the S&P 500 gained 0.71% and 1.92%. Year-to-date, the company has outperformed the benchmark with a return of 21.55% compared to the S&P 500's 16.30%. Overall, the current technical stance is mildly bullish, supported by several indicators, but recent performance against the S&P 500 highlights some short-term weakn..."
},
{
"title": "Fulgent Genetics Hits New 52-Week High at $23.57",
"link": "https://www.marketsmojo.com/news/stocks-in-action/fulgent-genetics-hits-new-52-week-high-at-2357-3588407",
"imagepath": "https://i.marketsmojo.com/newsimg/2025/10/FulgentGenetics_priceRelatedfactors_3588407.png",
"date": "2025-10-02 22:40:18",
"description": "Fulgent Genetics, Inc. has achieved a new 52-week high, reflecting a year-over-year performance increase. With a market capitalization of USD 682 million, the company faces challenges, including a negative return on equity and no dividend yield, as it navigates the competitive biotechnology sector."
},
{
"title": "Is Fulgent Genetics, Inc. technically bullish or bearish?",
"link": "https://www.marketsmojo.com/news/stocks-in-action/is-fulgent-genetics-inc-technically-bullish-or-bearish-3547599",
"imagepath": "",
"date": "2025-09-20 19:59:01",
"description": "As of 12 September 2025, the technical trend for Fulgent Genetics, Inc. has changed from bullish to mildly bullish. The weekly MACD is bullish, while the monthly MACD is mildly bullish. Bollinger Bands indicate a bullish stance for both weekly and monthly periods. Moving averages are bullish on the daily timeframe. However, the KST shows a mildly bearish signal on the weekly and mildly bullish on the monthly, and the OBV is mildly bearish on the monthly. \n\nIn terms of returns, Fulgent Genetics has outperformed the S&P 500 over the past week and month, with returns of 1.08% and 4.51% respectively, but it has underperformed over the longer term, particularly in the 3-year and 5-year periods. Overall, the current stance is mildly bullish, supported by several bullish indicators, but tempered by mixed signals from KST and OBV...."
},
{
"title": "Is Fulgent Genetics, Inc. overvalued or undervalued?",
"link": "https://www.marketsmojo.com/news/stocks-in-action/is-fulgent-genetics-inc-overvalued-or-undervalued-3543920",
"imagepath": "",
"date": "2025-09-20 18:32:40",
"description": "As of 5 May 2023, the valuation grade for Fulgent Genetics, Inc. has moved from expensive to risky, indicating a shift in perception regarding its financial health and market position. The company appears to be overvalued, particularly given its negative earnings metrics and low valuation ratios. Key ratios include a Price to Book Value of 0.58, an EV to EBIT of -4.67, and an EV to EBITDA of -7.04, all of which suggest significant challenges in profitability and valuation relative to its assets and earnings.\n\nIn comparison to peers, Fulgent Genetics has a P/E ratio of -21.2754 and an EV to EBITDA of -8.0743, which are considerably worse than Ginkgo Bioworks Holdings, Inc., which has a P/E of -2.1642 and an EV to EBITDA of -0.7299. This stark contrast highlights the relative weakness of Fulgent's financial metrics within the industry. While specific return data is not available, the absence of positive retur..."
}
],
"total": 15,
"sid": "1243530",
"stock_news_url": "https://www.marketsmojo.com/news/fulgent-genetics-inc-1243530"
},
"announcements": "",
"corporate_actions": {
"msg": "No corporate action Found"
}
}

News and Views

Fulgent Genetics Hits New 52-Week High of $27.36, Reflecting Strong Growth

2025-11-10 17:21:52

Fulgent Genetics, Inc. has achieved a new 52-week high, reflecting a strong performance over the past year. With a market capitalization of USD 682 million, the company, despite being loss-making, demonstrates resilience in the competitive biotechnology sector, highlighted by its financial metrics and recent stock performance.

Is Fulgent Genetics, Inc. technically bullish or bearish?

2025-11-05 11:22:52

As of 31 October 2025, the technical trend for Fulgent Genetics, Inc. has changed from bullish to mildly bullish. The weekly MACD is bullish, while the monthly MACD is mildly bullish, indicating a positive momentum but with some weakening. The Bollinger Bands are bullish on both weekly and monthly time frames, supporting the upward price movement. Daily moving averages are also bullish. However, the RSI shows no signal on both weekly and monthly charts, and Dow Theory indicates no trend in either time frame. In terms of performance, Fulgent Genetics has underperformed the S&P 500 over the past year and three to five years, with returns of 5.88% and -39.61% respectively, compared to the S&P 500's 19.89% and 76.66%. Overall, the current stance is mildly bullish, but the strength is tempered by mixed signals and historical underperformance....

Fulgent Genetics, Inc. Experiences Revision in Stock Evaluation Amid Market Dynamics

2025-11-04 16:08:37

Fulgent Genetics, Inc. has recently revised its evaluation amid current market conditions. The stock price has seen a slight increase, with a year-to-date return surpassing the S&P 500. However, its longer-term performance remains below the broader market, reflecting ongoing challenges within the company and industry.

Is Fulgent Genetics, Inc. technically bullish or bearish?

2025-11-04 11:34:23

As of 31 October 2025, the technical trend for Fulgent Genetics, Inc. has changed from bullish to mildly bullish. The weekly MACD is bullish, while the monthly MACD is mildly bullish, indicating a positive momentum. The Bollinger Bands and KST also reflect a mildly bullish stance across both weekly and monthly time frames. Moving averages are mildly bullish on a daily basis. However, the RSI shows no signal for both weekly and monthly periods, suggesting a lack of strong momentum. In terms of performance, Fulgent Genetics has underperformed the S&P 500 over the past year and three to five years, with returns of 6.94% and -39.01% respectively, compared to the S&P 500's 19.89% and 76.66%. However, it has outperformed the S&P 500 year-to-date with a return of 25.12% versus 16.30%. Overall, the current technical stance is mildly bullish, but the long-term performance raises caution....

Is Fulgent Genetics, Inc. technically bullish or bearish?

2025-11-03 11:34:12

As of 31 October 2025, the technical trend for Fulgent Genetics, Inc. has changed from bullish to mildly bullish. The weekly MACD and KST indicators are bullish, while the monthly MACD and KST are mildly bullish. The Bollinger Bands and moving averages also reflect a mildly bullish stance across both weekly and monthly time frames. The Dow Theory supports a mildly bullish outlook as well. In terms of performance, the stock has underperformed the S&P 500 over the past week and month, with returns of -5.43% and -4.47% respectively, while it has outperformed the S&P 500 year-to-date with a return of 21.55% compared to 16.30%. However, over longer periods, the stock has significantly underperformed the benchmark. Overall, the current technical stance is mildly bullish....

Is Fulgent Genetics, Inc. technically bullish or bearish?

2025-11-02 11:18:48

As of 31 October 2025, the technical trend for Fulgent Genetics, Inc. has changed from bullish to mildly bullish. The weekly MACD is bullish, while the monthly MACD is mildly bullish. The Bollinger Bands and KST indicators are also showing mildly bullish signals across both weekly and monthly time frames. Moving averages on the daily chart indicate a mildly bullish stance. However, the RSI does not provide any signals for either time frame. In terms of performance, Fulgent Genetics has underperformed the S&P 500 over the past week and month, with returns of -5.43% and -4.47% respectively, while the S&P 500 gained 0.71% and 1.92%. Year-to-date, the company has outperformed the benchmark with a return of 21.55% compared to the S&P 500's 16.30%. Overall, the current technical stance is mildly bullish, supported by several indicators, but recent performance against the S&P 500 highlights some short-term weakn...

Fulgent Genetics Hits New 52-Week High at $23.57

2025-10-02 22:40:18

Fulgent Genetics, Inc. has achieved a new 52-week high, reflecting a year-over-year performance increase. With a market capitalization of USD 682 million, the company faces challenges, including a negative return on equity and no dividend yield, as it navigates the competitive biotechnology sector.

Is Fulgent Genetics, Inc. technically bullish or bearish?

2025-09-20 19:59:01

As of 12 September 2025, the technical trend for Fulgent Genetics, Inc. has changed from bullish to mildly bullish. The weekly MACD is bullish, while the monthly MACD is mildly bullish. Bollinger Bands indicate a bullish stance for both weekly and monthly periods. Moving averages are bullish on the daily timeframe. However, the KST shows a mildly bearish signal on the weekly and mildly bullish on the monthly, and the OBV is mildly bearish on the monthly. In terms of returns, Fulgent Genetics has outperformed the S&P 500 over the past week and month, with returns of 1.08% and 4.51% respectively, but it has underperformed over the longer term, particularly in the 3-year and 5-year periods. Overall, the current stance is mildly bullish, supported by several bullish indicators, but tempered by mixed signals from KST and OBV....

Is Fulgent Genetics, Inc. overvalued or undervalued?

2025-09-20 18:32:40

As of 5 May 2023, the valuation grade for Fulgent Genetics, Inc. has moved from expensive to risky, indicating a shift in perception regarding its financial health and market position. The company appears to be overvalued, particularly given its negative earnings metrics and low valuation ratios. Key ratios include a Price to Book Value of 0.58, an EV to EBIT of -4.67, and an EV to EBITDA of -7.04, all of which suggest significant challenges in profitability and valuation relative to its assets and earnings. In comparison to peers, Fulgent Genetics has a P/E ratio of -21.2754 and an EV to EBITDA of -8.0743, which are considerably worse than Ginkgo Bioworks Holdings, Inc., which has a P/E of -2.1642 and an EV to EBITDA of -0.7299. This stark contrast highlights the relative weakness of Fulgent's financial metrics within the industry. While specific return data is not available, the absence of positive retur...

View All News